RxDoctor Payments DataLook up a doctor →

John Pagel

Hematology & Oncology · Seattle, WANPI 1376633222

Payments from drug & device makers

$6,102,202in general payments, 2019–2025

Across 915 payments — averaging $6669.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.2M
  • Gilead$961K
  • Acerta Pharma LLC$780K
  • AstraZeneca$270K
  • Pharmacyclics LLC, An Abbvie Company$180K
  • AbbVie$115K
  • plus $637K from 17 others
$1,604in research payments, 2019–2025

Across 4 payments — averaging $401.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$1K
  • AstraZeneca$524
  • TG Therapeutics, Inc.$16

What the payments were for

  • Consulting fees$121,24717%
  • Speaking & faculty fees$540,45375%
  • Travel & lodging$54,9688%
  • Food & beverage$7,8971%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,102,202 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Other hematology & oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →